Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

/a> a clinical collaboration agreement with Portola Pharmaceuticals, Inc. and Bayer HealthCare to evaluate an investigational-stage antidote for Factor Xa inhibitors. This proof-of-concept study is scheduled to complete in the second half of 2013.

On March 4, 2012, Janssen announced the U.S. Food and Drug Administration issued a second complete response letter regarding a supplemental New Drug Application for XARELTO® for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome. Janssen is evaluating the letter and will respond to the agency's questions.

About XARELTO® (rivaroxaban)
XARELTO® works by blocking the blood clotting Factor Xa.  It is approved for six distinct uses:

  1. To reduce the risk of blood clots in the legs and lungs of people who have just had knee replacement surgery.
  2. To reduce the risk of blood clots in the legs and lungs of people who have just had hip replacement surgery.
  3. To reduce the risk of both hemorrhagic and thrombotic strokes as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem. There is limited information on how XARELTO® compares to a medicine called warfarin in reducing the risk of stroke when the effects of warfarin are well controlled.
  4. To treat people with pulmonary embolism (PE).
  5. To treat people with deep vein thrombosis (DVT).
  6. To reduce the risk of recurrence of DVT or PE following an initial six months of treatment for acute venous thromboembolism.

Janssen Research & Development, LLC, and Bayer HealthCare together are developing rivaroxaban.  Janssen Pharmaceuticals, Inc. holds U.S.
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Pepperl+Fuchs, a world ... MACTek Corporation, a leading provider of HART protocol ... to further extend its integrated solutions offerings and ... "We are pleased to add the ... said Jim Bolin , Pepperl+Fuchs, executive vice ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5
... JERUSALEM , June 2, ... oral drug delivery systems, announced,today that its subsidiary Oramed Ltd. ... ("Laser Detect"), an Israeli company listed on,the Tel Aviv Stock ... Entera Bio Ltd. ("Entera"). Under the terms of the agreement, ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today that it ... June 10, 2010 at The Grand Hyatt Hotel in New York, ... will discuss the Company,s business strategy and historical financial performance at 11:30 ... , Attendance at ...
Cached Medicine Technology:Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2015)... Greifensee, Switzerland (PRWEB) , ... September 01, 2015 ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , ... be presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Mercy Health (formerly ... devoted the 10th of its monthly Mercy Health: Helping You Be Well videos to ... in seven men. , In a concise video on Mercy Health’s YouTube channel, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care ... VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:MAP Health Management Launches the MAP Recovery Network 2
... or engineer? Sex hormones strongly influence people,s interests, ... according to psychologists. , "Our results provide strong ... characterized by working with things versus people," said ... with Sheri A. Berenbaum, professor of psychology and ...
... 1 (HealthDay News) -- The intensity of exercise, not the ... of living a longer life, a new study suggests. ... with high levels of cycling intensity lived 5.3 years longer, ... men with low intensity. Among female cyclists, those with ...
... IL A natural yellowing of the eye lens that absorbs ... of test volunteers, according to a,study in the September 1 issue ... discoloration worsened with age, so did the risk of insomnia. ... why sleep disorders become more frequent with increasing age," said Line ...
... hospitalization rates in adolescents and young adults aged 15 ... 2008 according to a study conducted by researchers at ... findings available today in Annals of Neurology , ... Child Neurology Society, report an increase in the prevalence ...
... the September issue of the Journal of the American ... in chest computed tomography (CT) scans. Chest CT is the ... the cause of clinical signs or symptoms of the chest, ... Regardless of the body region being scanned, dose ...
... , WEDNESDAY, Aug. 31 (HealthDay News) -- New research ... files could greatly improve care for diabetic patients by ... faster" at various kinds of medical clinics that had ... Cebul, a professor of medicine at Case Western Reserve ...
Cached Medicine News:Health News:Sex hormones impact career choices 2Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Increased prevalence of stroke hospitalizations seen in teens and young adults 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: